(Q34348272)

1 August 2017

1 reference

title

Prostate cancer gene therapy. (English)

1 reference

1 August 2017

0 references

1 reference

Ferrer FA

1

1 reference

1 August 2017

Rodriguez R

series ordinal

2

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Hematology / Oncology Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

497-508

1 reference

Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

CD28/B7 costimulation: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Gene therapy with physical methods of gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Urologic applications of gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

MHC antigens on human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Dendritic cell-based immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Antisense c-myc retroviral vector suppresses established human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Dendritic cell vaccines for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Gene therapy using adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970228-8

7 January 2021

10.1016/S0889-8588(05)70228-8

Identifiers

DOI

1 reference

1 August 2017

1 reference